Literature DB >> 28655412

Paraneoplastic syndromes associated with gynecological cancers: A systematic review.

Mathieu Viau1, Marie-Claude Renaud2, Jean Grégoire3, Alexandra Sebastianelli2, Marie Plante4.   

Abstract

A number of paraneoplastic syndromes have been described with gynecological cancers. These syndromes are induced by substances secreted by the tumor or by an immune response triggered by the cancer. Each system of the human body can be affected by different syndromes. Indeed, paraneoplastic syndromes occurring from tumors of the gynecologic tract were found to involve the nervous, ophthalmologic, dermatologic, rheumatologic, endocrine, hematologic and renal systems. These syndromes can manifest before, at the time, or after the diagnosis of cancer. They can also occur at the time of a recurrence. Knowledge about these syndromes is important for physicians caring for patients with cancers, as they can result in severe morbidity and must be treated appropriately. Literature regarding paraneoplastic syndromes associated with tumors of the female genital tract is scattered and the subject has not been reviewed recently. A systematic literature search was thus conducted to identify paraneoplastic syndromes associated with gynecologic cancers. This review focuses on the cancers involved with each paraneoplastic syndrome, and on their pathophysiology, clinical manifestations, possible complications, outcomes, and treatments. As the mainstay of treatment in these conditions is often to address the underlying tumor, it is of upmost importance that physicians be aware of these rare cancer manifestations.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Paraneoplastic dermatoses; Paraneoplastic neurological syndromes; Paraneoplastic syndromes

Mesh:

Year:  2017        PMID: 28655412     DOI: 10.1016/j.ygyno.2017.06.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Paraneoplastic syndrome in neuroophthalmology.

Authors:  Longdan Kang; Chao Wan
Journal:  J Neurol       Date:  2022-07-02       Impact factor: 6.682

2.  Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study.

Authors:  Liping Cai; Heli Wu; Chunhua Tu; Xiaochun Wen; Bei Zhou
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

3.  Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.

Authors:  Guillaume Manson; Alexandre Thibault Jacques Maria; Florence Poizeau; François-Xavier Danlos; Marie Kostine; Solenn Brosseau; Sandrine Aspeslagh; Pauline Du Rusquec; Maxime Roger; Maud Pallix-Guyot; Marc Ruivard; Léa Dousset; Laurianne Grignou; Dimitri Psimaras; Johan Pluvy; Gilles Quéré; Franck Grados; Fanny Duval; Frederic Bourdain; Gwenola Maigne; Julie Perrin; Benoit Godbert; Beatris Irina Taifas; Alexandra Forestier; Anne-Laure Voisin; Patricia Martin-Romano; Capucine Baldini; Aurélien Marabelle; Christophe Massard; Jérôme Honnorat; Olivier Lambotte; Jean-Marie Michot
Journal:  J Immunother Cancer       Date:  2019-12-03       Impact factor: 13.751

4.  Metastatic Breast Cancer Masked as Constipation.

Authors:  Edwin McCray; Robyn Naron; Sarah White; Sarah Messersmith; Christopher Stewart
Journal:  Cureus       Date:  2021-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.